Follow the Tourmaline Bio, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was disclosed on 28 October 2025 (U). Among the most active insiders: Kulkarni Sandeep Chidambar. Every trade is free.
36
Insider Decl.
n/a
Thresholds
€3m
9 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Tourmaline Bio, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
49Σ signal
Buys €3mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
4,650 shares@ US$10.6823.6% of flowCommon StockSEC:0001209191-23-053691:0
Canonical exit: 22 Jan 2024 (T+90)
25 of 36 declarations
About Tourmaline Bio, Inc.
Tourmaline Bio, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. It is listed on the NASDAQ under the ticker TRML.